Bacterial biofilm infections are among the leading causes of morbidity and mortality among patients with cystic fibrosis or those with weakened immune systems. Treatment for biofilm infections usually entails intensive antibiotic therapy. There is an urgent need for well-designed agents to achieve in vivo diagnosis and precise anti-biofilm therapy without bacterial resistance. Unfortunately, no effective agent has been designed to perform these tasks adequately.
